TW202310856A - 含有源自血液之成長因子的組成物及其調製方法 - Google Patents
含有源自血液之成長因子的組成物及其調製方法 Download PDFInfo
- Publication number
- TW202310856A TW202310856A TW111118266A TW111118266A TW202310856A TW 202310856 A TW202310856 A TW 202310856A TW 111118266 A TW111118266 A TW 111118266A TW 111118266 A TW111118266 A TW 111118266A TW 202310856 A TW202310856 A TW 202310856A
- Authority
- TW
- Taiwan
- Prior art keywords
- blood
- platelet
- rich plasma
- aforementioned
- minutes
- Prior art date
Links
- 239000008280 blood Substances 0.000 title claims abstract description 122
- 210000004369 blood Anatomy 0.000 title claims abstract description 121
- 239000003102 growth factor Substances 0.000 title claims abstract description 111
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 238000000034 method Methods 0.000 claims abstract description 50
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 28
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 28
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 10
- 210000004623 platelet-rich plasma Anatomy 0.000 claims description 81
- 238000005119 centrifugation Methods 0.000 claims description 34
- 210000000601 blood cell Anatomy 0.000 claims description 32
- 238000007710 freezing Methods 0.000 claims description 25
- 230000008014 freezing Effects 0.000 claims description 25
- 238000010257 thawing Methods 0.000 claims description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 210000002381 plasma Anatomy 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 11
- 239000011148 porous material Substances 0.000 claims description 10
- 150000004697 chelate complex Chemical class 0.000 claims description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000017423 tissue regeneration Effects 0.000 abstract description 5
- 208000014674 injury Diseases 0.000 abstract description 2
- 230000008733 trauma Effects 0.000 abstract description 2
- 102000004127 Cytokines Human genes 0.000 description 37
- 108090000695 Cytokines Proteins 0.000 description 37
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 28
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 28
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 22
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 22
- 230000003110 anti-inflammatory effect Effects 0.000 description 20
- 238000000926 separation method Methods 0.000 description 17
- 230000002757 inflammatory effect Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 238000009777 vacuum freeze-drying Methods 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 238000005057 refrigeration Methods 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000014429 Insulin-like growth factor Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 108010081589 Becaplermin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 208000000491 Tendinopathy Diseases 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
- -1 carbonic acid hydrogen salt Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 2
- 230000008472 epithelial growth Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 206010028331 Muscle rupture Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000023835 Tendon disease Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-082782 | 2021-05-14 | ||
| JP2021082782A JP7025070B1 (ja) | 2021-05-14 | 2021-05-14 | 血液由来成長因子含有組成物及びその調製方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202310856A true TW202310856A (zh) | 2023-03-16 |
Family
ID=81124371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111118266A TW202310856A (zh) | 2021-05-14 | 2022-05-16 | 含有源自血液之成長因子的組成物及其調製方法 |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP7025070B1 (ja) |
| KR (1) | KR20240007208A (ja) |
| TW (1) | TW202310856A (ja) |
| WO (1) | WO2022239870A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7175055B1 (ja) | 2021-05-14 | 2022-11-18 | セルソース株式会社 | 血液由来成長因子含有組成物及びその調製方法 |
| WO2024122618A1 (ja) * | 2022-12-07 | 2024-06-13 | セルソース株式会社 | 成長因子含有組成物の調製方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
| EP2133086A4 (en) | 2007-03-07 | 2011-11-30 | Jms Co Ltd | PROCESS FOR PREPARING SERUM AND APPARATUS FOR PREPARING SERUM |
| EP2337617A4 (en) * | 2008-10-09 | 2013-06-12 | Bioparadox Llc | SQUARE PLASMA FORMULATIONS FOR HEART TREATMENTS |
| CA2810202C (en) | 2010-09-03 | 2018-02-20 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| CA2866480A1 (en) * | 2014-09-30 | 2016-03-30 | Antnor Limited | Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid |
| JP6875619B2 (ja) | 2015-02-26 | 2021-05-26 | 株式会社細胞応用技術研究所 | 多血小板血漿の保存方法 |
| JP2017171597A (ja) | 2016-03-22 | 2017-09-28 | 株式会社細胞応用技術研究所 | 血小板濃縮製剤の製造方法 |
| TWI744300B (zh) | 2016-03-23 | 2021-11-01 | 里爾中央醫學中心 | 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途 |
| KR102516995B1 (ko) | 2016-04-05 | 2023-03-31 | 제네럴 일렉트릭 컴퍼니 | 조정가능한 성장 인자 레벨을 가진 활성화된 혈소판 조성 |
| EP3254684B1 (en) | 2016-06-08 | 2019-10-23 | Lysatpharma GmbH | Human platelet lysate or fraction enriched in human platelet-derived extracellular vesicles, for use in medicine |
-
2021
- 2021-05-14 JP JP2021082782A patent/JP7025070B1/ja active Active
-
2022
- 2022-05-13 WO PCT/JP2022/020281 patent/WO2022239870A1/ja active Application Filing
- 2022-05-13 KR KR1020237042292A patent/KR20240007208A/ko unknown
- 2022-05-16 TW TW111118266A patent/TW202310856A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022175958A (ja) | 2022-11-25 |
| JP7025070B1 (ja) | 2022-02-24 |
| WO2022239870A1 (ja) | 2022-11-17 |
| KR20240007208A (ko) | 2024-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202310856A (zh) | 含有源自血液之成長因子的組成物及其調製方法 | |
| RU2735139C2 (ru) | Полученные из лизата тромбоцитов человека внеклеточные везикулы для применения в медицине | |
| US12036325B2 (en) | Purified exosome products, method of making, and methods of using | |
| EP2884992B1 (en) | A method of preparing a growth factor concentrate derived from human platelets | |
| JP6649257B2 (ja) | 濃厚血小板から誘導可能な生理活性組成物並びにその調製方法及び使用方法 | |
| US20220395623A1 (en) | Methods for isolating umbilical cord blood plasma products, tissue and cellular exosomes, and compositions and methods of use thereof | |
| US8993733B2 (en) | Procedure for obtaining a composition containing growth factors from a blood compound, and composition obtained by said procedure | |
| JP6391872B1 (ja) | 成長因子混合物およびその調製方法 | |
| EP3068410B1 (en) | Method for obtaining a cytokine-rich composition and composition obtained by means of this method | |
| JPWO2020227149A5 (ja) | ||
| JP7175055B1 (ja) | 血液由来成長因子含有組成物及びその調製方法 | |
| JP2007001968A (ja) | 血小板、赤血球、無核細胞及び血小板を含む組成物が体外にて保存できる媒体と方法。 | |
| WO2024122618A1 (ja) | 成長因子含有組成物の調製方法 | |
| CN115644168B (zh) | 一种成品免疫细胞的冻存液及其制备方法和冻存方法 | |
| KR20150061806A (ko) | 활성화된 혈소판 풍부 혈장을 유효성분으로 포함하는 동물의 창상 치료용 수의학적 조성물 | |
| WO1993007745A1 (en) | Method for freezing engrafting cells | |
| US20180133256A1 (en) | Process for removing growth factors from platelets | |
| WO2013039411A1 (en) | Autologous and allogenic fibrin carrier, method of obtaining thereof and use of a fibrin carrier for transplantation of cells, particularly human cells | |
| TWI678207B (zh) | 血小板乾粉製造方法 | |
| CN114306250B (zh) | 一种醋酸特利加压素制剂及其制备方法 | |
| EP4292598A1 (en) | A growth factor enriched dry powder and the use thereof for relieving inflammation or injury | |
| US20220280606A1 (en) | Method of preparing a de-fibrinated platelet lysate, and uses of said method | |
| MANCHANDA et al. | DIFFERENT TYPES OF PRP | |
| JP2023184429A (ja) | 二次電池成長因子を豊富に含む乾燥粉末が炎症または損傷を緩和する一種の用途 | |
| TW202400629A (zh) | 一種富含生長因子的乾粉用於緩解發炎或損傷之用途 |